Skip to content

Study · Animal study (in vivo) · 2004

9 results

General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.

Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M

Arzneimittel-Forschung1 Jan 2004Cited by 3 (Europe PMC)

PMID15646371 (opens in a new tab)DOI10.1055/s-0031-1297042 (opens in a new tab)PepBankPUB-15646371
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In animal models, KP-102 at a pharmacological dose showed no obvious effect on the central nervous system.

    In plain wordsIn animals, KP-102 at a pharmacological dose had no obvious effect on the brain and nervous system.

    Peptide
    GHRP-2
    Outcome
    No significant changeCentral nervous system effects
    Study

    n: not reported in source

    various animal experimental models
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The administration of KP-102 showed no obvious effect at a pharmacological dose on the central nervous system.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In animal models, KP-102 had no significant effect on the autonomic nervous system and smooth muscle, with a minor exception for the ileum.

    In plain wordsIn animals, KP-102 had no significant effect on the autonomic nervous system or smooth muscle, apart from a small ileum effect.

    Peptide
    GHRP-2
    Outcome
    No significant changeAutonomic nervous system and smooth muscle effects
    Study

    n: not reported in source

    various animal experimental models
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-102 had no significant effect on the autonomic nervous system and smooth muscle
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In animal models, KP-102 had a negligible effect on the respiratory system.

    In plain wordsIn animals, KP-102 had a negligible effect on breathing.

    Peptide
    GHRP-2
    Outcome
    No significant changeRespiratory system effects
    Study

    n: not reported in source

    various animal experimental models
    Outcome group
    Adverse events · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was negligible effect on the respiratory and cardiovascular systems, digestive system, renal function and blood system after KP-102 treatment.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In animal models, KP-102 had a negligible effect on the cardiovascular system.

    In plain wordsIn animals, KP-102 had a negligible effect on the heart and blood vessels.

    Peptide
    GHRP-2
    Outcome
    No significant changeCardiovascular system effects
    Study

    n: not reported in source

    various animal experimental models
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was negligible effect on the respiratory and cardiovascular systems, digestive system, renal function and blood system after KP-102 treatment.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In animal models, KP-102 had a negligible effect on the digestive system.

    In plain wordsIn animals, KP-102 had a negligible effect on digestion.

    Peptide
    GHRP-2
    Outcome
    No significant changeDigestive system effects
    Study

    n: not reported in source

    various animal experimental models
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was negligible effect on the respiratory and cardiovascular systems, digestive system, renal function and blood system after KP-102 treatment.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In animal models, KP-102 had a negligible effect on renal function.

    In plain wordsIn animals, KP-102 had a negligible effect on kidney function.

    Peptide
    GHRP-2
    Outcome
    No significant changeRenal function effects
    Study

    n: not reported in source

    various animal experimental models
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was negligible effect on the respiratory and cardiovascular systems, digestive system, renal function and blood system after KP-102 treatment.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In animal models, KP-102 had a negligible effect on the blood system.

    In plain wordsIn animals, KP-102 had a negligible effect on the blood.

    Peptide
    GHRP-2
    Outcome
    No significant changeBlood system effects
    Study

    n: not reported in source

    various animal experimental models
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was negligible effect on the respiratory and cardiovascular systems, digestive system, renal function and blood system after KP-102 treatment.
  8. 08LabEx vivo tissueSafety outcome

    In isolated rabbit ileum, KP-102 at high doses caused a slight and transient increase in spontaneous motility.

    In plain wordsIn lab tests on rabbit gut tissue, high doses of KP-102 caused a slight, short rise in movement.

    Peptide
    GHRP-2
    Outcome
    IncreaseSpontaneous motility of isolated rabbit ileum
    Study

    rabbitn: not reported in source

    isolated rabbit ileum
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    high dosesAs given in this study (rabbit).

    Source sentences

    Summary
    except a slight and transient increase in spontaneous motility of isolated rabbit ileum and contraction of isolated guinea pig ileum at high doses.
  9. 09LabEx vivo tissueSafety outcome

    In isolated guinea pig ileum, KP-102 at high doses caused a slight and transient contraction.

    In plain wordsIn lab tests on guinea pig gut tissue, high doses of KP-102 caused a slight, short contraction.

    Peptide
    GHRP-2
    Outcome
    IncreaseContraction of isolated guinea pig ileum
    Study

    guinea pign: not reported in source

    isolated guinea pig ileum
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    high dosesAs given in this study (guinea pig).

    Source sentences

    Summary
    contraction of isolated guinea pig ileum at high doses

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.